President directs CMMI to consider new models to lower drug costs
President Biden today directed the Center for Medicare and Medicaid Innovation to consider new payment and delivery models to lower drug costs and promote access to innovative drug therapies for beneficiaries, and report within 90 days on its plan and timeline for testing selected models. AHA will update members as more information on the plan becomes available.
Related News Articles
Blog
The health care field has entered a period of disruption, from sweeping coverage changes to the rise of artificial intelligence (AI)-enabled tools. The…
Chairperson's File
In last month’s Chair File, we talked about some of the key priorities the AHA has for the remainder of 2025, one of which is protecting the 340B Drug Pricing…
Headline
The Centers for Medicare & Medicaid Services is launching a new initiative for state Medicaid programs to purchase prescription drugs at prices aligned…
Headline
The AHA and a coalition of organizations yesterday urged House and Senate leaders to pass the Reforming and Enhancing Sustainable Updates to Laboratory Testing…
Headline
The Health Resources and Services Administration posted on its website that it had approved eight drug company plans for participation in the 340B Rebate Model…
Headline
The Senate Committee on Health, Education, Labor and Pensions Oct. 23 held a hearing discussing the 340B Drug Pricing Program and its growth and impacts on…